Boston starts EPIC new stent trial
This article was originally published in Clinica
Executive Summary
Boston Scientific has begun a trial of its next-generation EPIC self-expanding nitinol stent system in patients with iliac artery disease. In the disorder, a patient's iliac arteries, which carry blood to the legs, become blocked. The ORION study will enrol 123 patients at 25 US sites, and will measure rates of device- and/or procedure-related major adverse events at nine months. These events are death within 30 days, myocardial infarction occurring during related hospitalisation, target vessel revascularisation, and amputation of the treated limb. The trial will incorporate stent diameter ranges of 6-12mm and lengths up to 120mm. Natick Massachusetts-based Boston launched EPIC in Europe last month, but it is not approved in the US.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.